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a r t i c l e i n f o a b s t r a c tKeywords:
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Duplex assay
Antibody cross-reactionThis paper reports the development of an easy to use antibody microarray-based immunoassay platform
for sensitive and selective duplex detection of PSA (prostate speciﬁc antigen) and hK2 (human kallikrein
2). Using PDMS wells in a 3  9 array on epoxy-coated glass slides 27 duplex immunoassays can be
performed in parallel. Automated microarraying provided fast and reproducible antibody arraying in each
assay well. To achieve highly sensitive and selective detection of each biomarker, we evaluated and
optimized the density of each of the immobilized capture antibodies. The assay platform showed a limit
of detection (LOD) of each biomarker (PSA and hK2) of less than 10 pg/mL and a dynamic range of
104–105 orders of magnitude. Neither the PSA nor the hK2 antibody array showed any cross-reaction
against each others target proteins or other plasma proteins. These results emphasize the importance
of density optimization of capture antibody on the surface in order to achieve a sensitive and selective
multiplex immunoassay.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Increasing levels of PSA in the blood circulation can be caused
by prostate cancer (PCa), but it also appears at benign prostate dis-
eases since elevated PSA is speciﬁc to prostate disorders and not
only to PCa. In male blood, PSA levels vary from <0.1 ng/mL to
10 lg/mL [1], though elevated levels above 4 ng/mL recommend
further diagnostic steps to be taken including prostate biopsy.
Studies of larger cohorts show that men with PSA above this
threshold had cancer detection rates of 27–44% [2,3]. On the other
hand, there are several studies reporting that prostate cancer were
detected in 6.6% of the men with a PSA level less than 0.5 ng/mL
PSA and in 27% of the men with PSA ranging from 3.1 ng/mL to
4 ng/mL [4,5]. PSA screening tests are reported to have a signiﬁcant
correlation with a 20% reduction in cancer mortality, however it
has drawbacks such as leading to unnecessary and painful biopsies
due to the low speciﬁcity of the PSA assay [6,7]. Therefore, require-
ment for additional prostatic tumor markers are increasingly high.
Human glandular kallikrein 2 (hK2) is a serine protease having
structurally similarity with PSA [8,9] and monomeric polypeptidesof 237 amino acid residues having around 80% sequential
homology to PSA [10]. hK2 has been considered as another PCa bio-
marker since the hK2 levels are increased in serum from PCa
patients relative to individuals with benign prostate hyperplasia
(BPH) [11,12]. Moreover, hK2 is known to act as an independent
predictor of PCa diagnosis in case of mildly elevated PSA level
between 4 ng/mL and 10 ng/mL so called ‘‘gray zone’’ [13,14]. Con-
centration of hK2 in human prostate is approximately 10–50% of
the PSA level and it is 50- to 100-fold lower than that of the PSA
concentration in human blood [15,16]. Considering PSA’s cut-off
range (4 ng/mL), the hK2 assay should need more sensitive
detection with a limit of detection (LOD) of 40 pg/mL or lower.
Antibody microarrays are known to have potential for high
throughput multiplex screening of biomarkers and is also proposed
as a tool for the detection of low abundant protein biomarkers in
human bioﬂuids such as serum, urine and cerebrospinal ﬂuid
(CSF) [17]. The microarray format can ultimately offer advantages
in terms of a low amount of antibody consumption, highly
sensitive readout, and multiplex performance. Such developments
hold promise of earlier diagnosis of disease, reducing the need for
biopsy and providing post therapy monitoring of patients for
recurrence [18,19].
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(forward phase) immunoassay and reverse phase assay [20–22].
Sandwich immunoassays have the advantages of sensitive and
selective detection of antigen since two antibodies are used for
speciﬁcally captured and enrichment of the antigen and followed
by speciﬁc detection of the captured species. It is also a suitable
method for the detection of antigens in complex samples since
crude bioﬂuids can be analyzed with no minimal sample pretreat-
ment before performing the assay [23]. To improving the detection
sensitivity of the sandwich type immunoassay, optimizations of
the capture antibody such as afﬁnity or/and surface density are
one of most important steps in microarray format [24] since a
major hurdle in sensitive assaying is the elimination of antigen
cross-reaction and unspeciﬁc binding to antibodies.
We propose a simple and robust microarray immunoassay
platform for simultaneous detection of two prostate cancer related
biomarkers (PSA and hK2) in serum. Fig. 1 shows the layout of the
platform, which simultaneously incorporates a standard curve and
real sample assaying. PDMS wells in a 3  9 format were
assembled on epoxy coated slide glass. Epoxysilane based surface
chemistry was selected for its high binding capacity and the known
low background noise [25,26]. The two ﬁrst 9 well rows were
reserved to assaying a standard curve for PSA and hK2 (standard
samples). The last 9 wells were dedicated to immunoassaying
PSA and hK2 spiked serum samples (see Fig. 2b).
4  4 antibody arrays were spotted in each well. For best per-
formance of the immunoassay platform, we evaluated three con-
centrations of the two spotted capture antibodies and measured
ﬂuorescent signals of both target proteins, PSA and hK2. By optimi-
zation of the capture antibody concentration, an excellent sensitiv-
ity of each of the two biomarkers, PSA and hK2, was obtained with
a LOD (limit of detection) less than 10 pg/mL for both assays. More-
over, a 104–105 order of magnitude dynamic range, depending on
the concentration of the capture antibody of PSA and hK2 assay
was obtained. The platform allows measuring both standard sam-
ples and complex samples in parallel and this makes it possible to
reduce analytical error of slide-to-slide variance.
Since PSA has structural similarity to hK2, cross-reaction tests
were of utmost importance, which is shown in the unspeciﬁcFig. 1. Schematic layout of the assay platform and experimental procedures. The antibo
aligned to the arrayed parts and assembled to the glass slide. Samples and detection antib
spot arrays were imaged for analysis.binding between PSA antibody against hK2, and hK2 antibody
against PSA respectively. To evaluate the degree of cross-reaction,
we designed a duplex assay format such that PSA and hK2
antibodies were spotted on the same surface in an assay well.
Under optimized capture antibody conditions, we obtained a
sensitive and selective detection both PSA and hK2 using the
immunoassay platform with no detectable cross-reaction above
background noise.2. Material and methods
2.1. Proteins and reagents
The monoclonal mouse antibody against PSA (5A6, 4P33) was
obtained by HyTest Ltd., Turku, Finland. The polyclonal sheep
anti-PSA antibody and Alexa Fluor 488 labeled donkey anti-sheep
antibody were purchased from Abcam, Cambridge, UK (ab35355)
and Jackson ImmunoReaserch, West Grove, PA, USA (713-545-
003), respectively. The monoclonal mouse antibody against hK2
(6B7, ab40749) was purchased from Abcam. The polyclonal goat
anti-hK2 antibody (PAB7226) and Alexa Fluor 488 labeled donkey
anti-goat (ab35355) antibody were purchased from Abnova and
Abcam, respectively. Recombinant human PSA (P3338) and hK2
(ATGP2175) were obtained from Sigma–Aldrich and ATGen,
respectively.
2.2. Human female serum spiked with PSA and hK2
Female single donor serum was purchased by SCIPAC (S122-1),
and stored at 80 C. The serum was spiked with PSA and hK2 in a
titration series ranging from 1 pg/mL to 1 lg/mL.
2.3. Sandwich assay
Epoxy coated glass substrate has a great advantage to realize
antibody microarrays since they show good spot quality, low back-
ground noise [25,26]. Monoclonal mouse capture antibodies were
spotted in 4  4 arrays (spot to spot distance; 800 lm) on epoxydy microarray is spotted on the epoxy coated glass slide, and a PDMS well slab was
ody were then incubated in each well for the immunoassay. Finally, the ﬂuorescent
Fig. 2. The format of the immunoassay platform. Antibody microarrays were
spotted in 4  4 arrays on the epoxy glass using a piezo-electric driven microarrayer
(Scienion DW) for (a). PDMS wells (5 mm diameter) were punched in a 3  9 array
and bonded to the epoxy glass before performing the immunoassay (b).
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A piezoelectric microarrayer (DW scienion AB) can spot 300 pL per
droplet. One spot volume of the array was 2.7 nL by dispensing 16
drops (4  4 arrays). Antibodies were immobilized on the surface
by covalent bonding between the amine group in antibodies to
the epoxysilane on the surface of the glass slide. Two antibodies,
5A6 and 6B7, were spotted in the well for targeting PSA and hK2,
respectively. The slide glass was then assembled with the PDMS
(Dimethylpolysiloxane) well. The 25  70 mm size and 2 mm
thickness PDMS slab was prepared to ﬁt the well format as in
Fig. 2b. A prepolymer of PDMS (Silopt 184, Dow Corning Toray)
was mixed with a curing reagent in a 10:1 weight ratio, and poured
over the mold master. The mixture was kept at around 0.02 MPafor 30 min in a vacuum chamber to remove the trapped air bubbles
from the liquid PDMS. After curing, 5 mm holes were punched in a
3  9 array on the PDMS slab to deﬁne the PDMS well, following a
96 well array format. The slab was cut to ﬁt the glass slide foot
print 25 mm by 75 mm. The prepared PDMS slab was subsequently
autonomously bonded onto the epoxy coated slide glass.
The platform was evaluated using samples with PSA and hK2
spiked into both pure buffer (PBS) and female serum to obtain a
ﬁnal concentration ranging from 1 pg/mL to a few 1 lg/mL.
The following steps were performed at room temperature:
1. After arraying the antibody in the wells, they were washed
three times using 10 mM PBS, to remove loosely bound
antibodies.
2. The wells were incubated for 1 h in 100 lL blocking solution
(5% (w/v) non-fat dry milk in PBS (Bio-Rad)) to prevent non-
speciﬁc binding and washed 3 times using 0.05% Tween-20 in
10 mM PBS.
3. Following blocking, the platform was incubated with 50 lL of
spiked sample for 1 h, then washed (as above) and subse-
quently incubated with 50 lL of detection antibody (polyclonal
sheep anti-PSA in case of the PSA assay and polyclonal goat
anti-hK2 for the hK2 immunoassay).
4. After another washing step, 50 lL of AF488 labelled anti-sheep
polyclonal antibody (1 lg/mL) or AF488 labelled anti-goat
polyclonal antibody (1 lg/mL) was added onto the platform
for PSA and hK2 immunoassay respectively, and the platform
was incubated for 1 h.
5. Finally, the platform was washed 3 times and dried at room
temperature.
6. The ﬂuorescent spots images were observed using a Nikon
eclipse TE2000-U.
7. The captured images were analyzed by Image J software.
2.4. Fluorescence measurement
The mean intensities of spots were measured and quantiﬁed by
an open source of image processing tool, Image J (http://rsbweb.
nih.gov/ij/). We selected 4 (2  2 array) spots of each well for
quantiﬁcation of the data, which means totally 4 spots were
chosen for data analysis. All experiments were performed on 2
independent chips. The intensities of spot circles (S) were
measured and quantiﬁed across the area. Local background (B)
was collected in the same way and subtracted from the spot sig-
nals, generating mean spots intensities (S-B) as presented in the
graphs. The limit of detection (LOD) was deﬁned as the lowest
detectable signal from 3-sigma standard deviation (3r) above
the mean spot intensity of the negative control (N).3. Results and discussion
3.1. General remark
Generally, optimizations of the capture antibody such as afﬁnity
or/and density are greatly important to improve sensitivity of a
sandwich type immunoassay in microarray format [23]. The assay
platform has totally 27 wells, which was divided in three parts.
First two parts (3  3 wells each) were replicates of PSA and hK2
standard samples and the last one was dedicated to real samples.
3.2. PSA immunoassay optimization by varying the concentration of
the capture antibody
The assay sensitivity was optimized by varying the concentra-
tion of the spotted capture antibody. Three different concentrations
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immunoassay. Fig. 3 shows a titration series of PSA against the cap-
ture antibody concentrations. Increasing concentrations of capture
antibody yielded elevated ﬂuorescent signals. However, the nega-
tive control (N) signal also increased at higher density of the anti-
body. Mean value of the negative control at 90 lg/mL of capture
antibody was 7.22 and it becomes 8.9 at 180 lg/mL antibody con-
centration. It drastically increased up to 18.0 at 360 lg/mL of the
antibody concentration (see Supplementary Fig. S-1). Limit of
detection (LOD) was deﬁned as 3 sigma (r) above that of negative
control (N). The best PSA titration plot was found for a capture anti-
body concentration (5A6) of 180 lg/mL. The LOD was lower than
10 pg/mL with four order of magnitude dynamic range (10 pg/mL
to 100 ng/mL). The within chip spot reproducibility displayed a
CV of10–20% (see Fig. S-1). The linear regression of the mean spot
intensities versus PSA concentration corresponded to a coefﬁcient
of determination (R2) equal to 0.96 for capture antibody concentra-
tions 180 lg/mL. On the other hand, LOD became deteriorated
when capture antibody concentrations were 90 lg/mL or 360
lg/mL. In case of the 90 lg/mL capture antibody concentration,
the 3 sigma above the negative control (NC) was found to be just
above a PSA level of 1 ng/mL (Fig. 3 insert). The dynamic range
was found to be two to three orders of magnitude.
A further increased density of capture antibody (360 lg/mL) did
not yield any improved LOD since the NC level also drastically
increased as compared to that of the array with capture antibody
concentration of 180 lg/mL (see Fig. 3 lower). The increased NC
level is a natural effect of an elevated capture antibody concentra-
tion that increases unspeciﬁc binding to secondary and detection
antibodies. At an antibody concentration of 360 lg/mL the LOD
was estimated to 10 ng/mL.3.3. PSA immunoassay in female human serum
The developed microarray platform was subsequently evalu-
ated in human serum samples. As shown in the Fig. 2b, the plat-
form can cover both duplicate of standard sample (PSA in PBS
buffer) and real sample (PSA spiked serum).
We chose to spot the optimal capture antibody concentrations
of 180 lg/mL, Fig. 3. PSA spiked serum samples were prepared
according to the following. Initially, a high concentration ofFig. 3. Titration series of PSA in buffer (PBS) solution at three different concentra-
tions of the capturing antibody 5A6 (90 lg/mL, 180 lg/mL and 360 lg/mL). The
LOD was found to be 10 pg/mL when the capturing antibody was 180 lg/mL and
increased to 1 ng/mL when the capturing antibody concentrations were 180 and
360 lg/mL.recombinant PSA (over few lg/mL) was spiked into a serum sam-
ple and the spiked samples were serially diluted up to 106 times in
serum to achieve total PSA levels ranging from a pg/mL to a hun-
dred ng/mL. As a negative control we assayed un-spiked serum.
The PSA-spiked serum samples were assayed simultaneously with
a duplicate of the standard sample (PSA-spiked PBS) on the same
glass slide, see Fig. 2b.
In Fig. 4, the corresponding titration series of PSA in female
serum and PSA spiked in PBS buffer as recorded on the micro-
arrays. The LOD was found to be around 10 pg/mL. It was also
noted that the signal intensities of PSA-spiked serum samples were
signiﬁcantly lower (about 30%) than those obtained with PSA in
PBS buffer. This result agrees with the 30–40% loss of immunoac-
cessible PSA seen in earlier studies using puriﬁed PSA added to
serum [27,28]. It was also noted that the dynamic range of PSA
spiked serum samples was the same as the standard (PBS) samples
(4 orders of magnitude; 10 pg/mL to 100 ng/mL).
3.4. hK2 immunoassay optimization by concentration changing
capture antibody
Analogous to the PSA immunoassay development, we evaluated
the hK2 assay sensitivity by arraying the hK2 capture antibody,
6B7, at three different concentrations and performed the hK2
immunoassay in buffer solution. In Fig. 5 the microarray ﬂuores-
cence readout versus the hK2 concentration is presented for three
different antibody concentrations (50, 100 and 200 lg/mL). The
LOD for hK2 at an antibody concentration of 50 lg/mL was found
to be 50 pg/mL (dynamic range: 104). An increased concentration
of the capture antibody yielded an improved the LOD of 5 pg/mL
at an antibody concentration of 100 lg/mL with a dynamic range
of ﬁve orders of magnitude. However, the negative control (N) dis-
played an elevated signal above zero caused by unspeciﬁc binding
between capturing antibody and its binding partner (such as
secondary or the detector antibody) that at a further increased
antibody concentration (200 lg/mL).
Moreover, the dynamic range was reduced to about two orders
of magnitude. It was concluded that the hK2 microarray immuno-
assay displayed an optimal performance when arraying the cap-
ture antibody at a concentration of 100 lg/mL. Within chip spot
reproducibility displayed CVs of 10–25% (see Fig. S-2). The linear
regression of the mean spot intensities versus PSA concentration
corresponded to a coefﬁcient of determination (R2) of 0.99 using
a capture antibody concentration of 100 lg/mL.
3.5. hK2 immunoassay in female serum
Since an hK2 antibody concentration of 100 lg/mL showed the
best assay performance, we spotted the capture antibody in 4  4
format and evaluated the immunoassay in hK2-spiked serum in
parallel standard sample duplicate (PSA in PBS buffer) according
to the format depicted in Fig. 2b.
The titration series of both hK2 standard (hK2 spiked PBS) and
hK2 serum sample (hK2 spiked female serum) are plotted in Fig. 6.
The LOD was found to be around a few pg/mL (3r above NC deﬁ-
nition). The dynamic range of both titration series was four orders
of magnitude (few pg/mL to 100 ng/mL) and intensities of micro-
array signal of hK2-spiked serum samples were at maximum 30%
lower than the hK2 signal obtained in PBS buffer. Most of the
microarray experiments had a coefﬁcient of variation (CV) of less
than 25%, indicating good spot reproducibility of the chips.
3.6. Antibody cross-reaction toward duplex assay format
Cross-reaction between an antibody and non-speciﬁc antigens
in serum could be a major hurdle to develop sensitive and selective
Fig. 4. Comparison of PSA titration spiked in both PBS buffer and serum sample. The optimal concentration of capture antibody was chosen to 180 lg/mL. A standard sample
(PSA spiked PBS) was titrated (1 pg/mL–100 ng/mL) and assayed in duplicate wells in parallel with the assaying of PSA spiked serum, titrated over the range 1 pg/mL–100 ng/
mL.
Fig. 5. Titration series of hK2 in buffer (PBS) solution at three different concentra-
tions of the capturing antibody 5A6 (50 lg/mL, 100 lg/mL and 200 lg/mL). The
LOD was found to be 5 pg/mL at a capture antibody concentration of 100 lg/mL and
increased to 50 pg/mL and 500 pg/mL at a capture antibody concentration of 50 lg/
mL and 200 lg/mL respectively.
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cross-reaction between the PSA antibody (5A6) and hK2 antibody
(6B7) with respect to their corresponding target proteins. TheFig. 6. Comparison of hK2 titration both spiked in PBS buffer and serum sample. The o
microarray wells of standard sample (hK2 spiked PBS) were titrated and assayed over the
from 5 pg/mL to 500 ng/mL.upper part of Fig. 7 shows the duplex antibody array format. The
ﬁrst two rows comprised the PSA antibody (5A6) spotted in a con-
centration of 180 lg/mL and the last two rows comprised the hK2
antibody (6B7) spotted in a concentration of 100 lg/mL. Fig. 7a
shows the titration series of PSA spiked into serum at a concentra-
tion from 500 fg/mL to 5 lg/mL and Fig. 7b displays the corre-
sponding titration of hK2 spiked serum. In the ﬁgure, both
assayed signals were plotted in a single graph to visualize a poten-
tial sensitivity to cross-reaction. LOD and dynamic range of the PSA
assay was similar to the single-plex assay (Fig. 4). Using 3r deﬁni-
tion, the LOD to PSA was found to be 5 pg/mL and the dynamic
range was found to be ﬁve orders of magnitude (5 pg/mL–
500 ng/mL). Above a PSA level of 5 lg/mL the ﬂuorescent signal
was saturated. Most importantly, there was no hK2 cross reaction
observed in the PSA assay. The corresponding titration of hK2
spiked in serum is seen in (Fig. 7b). The LOD was found to be
5 pg/mL at 3r deﬁnition and the dynamic range was ﬁve orders
of magnitude (5 pg/mL–500 ng/mL). No signiﬁcant cross-reaction
between PSA antibody and hK2 was observed over the entire hK2
range. The optimized duplex microarray assay displays a broad
dynamic range of ﬁve orders of magnitude from 5 pg/mL to
500 ng/mL, which hold potential for detection of patients with
early tumor relapse after radical prostate ectomy. It should be sta-
ted that a more extensive evaluation in a larger clinical sample
cohort is needed to fully qualify the proposed duplex assay for clin-
ical investigations.ptimal concentration of the capture antibody was chosen to 100 lg/mL. Duplicate
range of 1 pg/mL–1 lg/mL simultaneous with a PSA spiked serum titration ranging
Fig. 7. To investigate the level of cross-reaction between antibodies against non-speciﬁc target proteins, a duplex antibody array was spotted on the substrate (top
schematic). Titration and immunoassaying of PSA spiked serum (500 fg/mL–5 lg/mL) was performed and the ﬂuorescent signals from the PSA antibody and the hK2 antibody
arrays were plotted (a). Conversely, hK2-spiked serum (from 500 fg/mL to 5 lg/mL) was also assayed on the duplex anti-PSA and anti-hK2 array. Using the 3 sigma above the
negative control as the deﬁnition for the LOD, this was found to be around 5 pg/mL with a dynamic range of ﬁve orders of magnitude (from 5 pg/mL to 500 ng/mL) (b).
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In this work, we developed a duplex microarray immunoassay
platform for PSA and hK2. By optimization of the concentration
of the spotted capture antibody, the platform displayed an LOD
of 5 pg/mL in spiked serum samples for both target proteins with-
out any signiﬁcant cross-reaction or interference from unspeciﬁc
binding. Our assay platform has comparable sensitivity to other
ultra-sensitive detection methods such as nano-particle based
detection method [29,30], single molecular digital ELISA systems
[31,32], 3-D porous silicon assay platforms [33,34] for PSA detec-
tion and highly optimized ELISA system for hK2 detection
[35,36]. Moreover, this platform showed selectivity to the target
biomarker as compared to the counter antigen, PSA and hK2
respectively.
The optimization procedure described herein enables the
development of multiplex antibody microarrays for simultaneous
measurement of several biomarkers related to prostate cancer. As
an initial step towards a truly multiplex assay we realized an opti-
mized duplex assay of both PSA and hK2 spiked in serum. Several
other proteins in the human kallikrein family have strong correla-
tions with malignant prostatic disease [37,38] and are thus in focus
accomplish a multiplex detection of these biomarkers and
potentially provide improved prostate cancer diagnostics.Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Acknowledgement
This study was partly supported by RIKEN FPR program and
JSPS KAKENHI Grant Number 25350581. This project is also sup-
ported by Korea Ministry of Environment as ‘‘EI project’’ (ERL
E211-41003-0007-0).Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.sbsr.2015.01.003.References
[1] H. Lilja, D. Ulmert, A.J. Vickers, Prostate-speciﬁc antigen and prostate cancer:
prediction, detection and monitoring, Nat. Rev. Cancer 8 (2008) 268–278.
[2] J. Hugosson, G. Aus, H. Lilja, P. Lodding, C.G. Pihl, Results of a randomized,
population-based study of biennial screening using serum prostate-speciﬁc
antigen measurement to detect prostate carcinoma, Cancer 100 (2004) 1397–
1405.
[3] G.L. Andriole, D. Levin, E.D. Crawford, E. Gelmann, P.F. Pinsky, D. Chia, B.S.
Kramer, D. Reding, T.R. Church, R.L. Grubb, G. Izmirlian, L.R. Ragard, J.D.
Clapp, P.C. Prorok, J.K. Gohagan, Prostate Cancer Screening in the Prostate,
Lung, Colorectal and Ovarian (PLCO) cancer screening trial: ﬁndings from
the initial screening round of a randomized trial, J. Natl. Cancer Inst. 97
(2005) 433–438.
[4] I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M. Scott Lucia, H.L.
Parnes, L.M. Minasian, L.G. Ford, S.M. Lippman, E.D. Crawford, J.J. Crowley, C.A.
Coltman, Prevalence of prostate cancer among men with a prostate-speciﬁc
antigen level 64.0 ng per Milliliter, N. Engl. J. Med. 350 (2004) 2239–2246.
[5] G. Aus, J.E. Damber, A. Khatami, H. Lilja, J. Stranne, J. Hugosson, Individualized
screening interval for prostate cancer based on prostate-speciﬁc antigen level
results of a prospective randomized, population-based study, Arch. Intern.
Med. 165 (2005) 1857–1861.
[6] A. Vickers, A. Cronin, M. Roobol, C. Savage, M. Peltola, K. Pettersson, P.T.
Scardino, F. Schroder, H. Lilja, Reducing unnecessary biopsy during prostate
cancer screening using a four-kallikrein panel: an independent replication, J.
Clin. Oncol. 28 (2010) 2493–2498.
[7] S.A. Strope, G.L. Andriole, Improving prostate-speciﬁc antigen screening, J. Clin.
Oncol. 28 (2010) 2491–2492.
[8] P. Riegman, R.J. Vliestra, J. Suurmeijer, C. Cleutjens, J. Trapman,
Characterization of human kallikrein locus, Genomics 14 (1992) 6–11.
[9] L.J. Schedlich, B.H. Bennetts, B.J. Morris, Primary structure of a human
glandular kallikrein gene, DNA 6 (1987) 429–437.
[10] T. Pironnen, B.O. Villoutreix, C. Becker, K. Hollingsworth, M. Vihinen, D. Bridon,
X. Qiu, J. Rapp, B. Dowell, T. Lovgen, K. Pettersson, H. Lilja, Determination and
analysis of prostate speciﬁc antigen (PSA) and human glandular kallikrein
2(hK2) using synthetic peptides and computer modeling, Protein Sci. 7 (1998)
259–269.
[11] C. Becker, T. Piironen, K. Pettersson, T. Bjork, K.J. Wojno, J.E. Oesterling, H. Lilja,
Discrimination of men with prostate cancer from those with benign disease by
measurements of human glandular kallikrein 2 (hK2) in serum, J. Urol. 163
(2000) 311–316.
[12] J.A. Finlay, C.L. Evans, J.R. Day, J.K. Payne, S. Mikolajczyk, L. Millar, K. Kuus-
Reichel, R. Wolfert, H. Rittenhouse, Development of monoclonal antibodies
speciﬁc for human glandular kallikrein (hK2): development of a dual antibody
immunoassay for hK2 with negligible prostate-speciﬁc antigen cross-
reactivity, Urology 51 (1998) 804–809.
[13] M. Kwiatkowski, F. Recker, T. Piironen, K. Pettersson, T. Otto, M. Wernli, R.
Tscholl, In prostatism patients the ratio of human glandular kallikrein to free
PSA improves the discrimination between prostate cancer and benign
hyperplasia within the diagnostic ‘‘gray zone’’ of total PSA 4 to 10 ng/mL,
Urology 52 (1998) 360–365.
[14] M.C. Charlesworth, C. Young, G. Klee, M. Saedi, S. Mikolajczyk, J. Finlay, D.
Tindall, Detection of a prostate-speciﬁc protein, human glandular kallikrein
S.W. Lee et al. / Sensing and Bio-Sensing Research 3 (2015) 105–111 111(hK2), in sera of patients with elevated prostate-speciﬁc antigen levels,
Urology 49 (1997) 487–493.
[15] P. Henttu, O. Lukkarinen, P. Vihko, Expression of the gene coding for human
prostate-speciﬁc antigen and related hGK-1 in benign and malignant tumors
of the human prostate, Int. J. Cancer 45 (1990) 654–660.
[16] M. van Gils, U.H. Stenman, J.A. Schalken, F.H. Schröder, T.M. Luider, H. Lilja, A.
Bjartell, F.C. Hamdy, K.S.I. Pettersson, R. Bischoff, H. Takalo, O. Nilsson, P.F.A.
Mulders, C.H. Bangma, Innovations in serum and urine markers in prostate
cancer current European research in the P-Mark project, Eur. Urol. 48 (2005)
1031–1041.
[17] B.B. Haab, M.J. Brown, P.O. Brown, Protein microarrays for highly parallel
detection and quantitation of speciﬁc proteins and antibodies in complex
solutions, in: Genome Biol. 2 (2001). RESEARCH0004.
[18] J.M. Jacobs, J.N. Adkins, W. Qian, T. Liu, Y. Shen, D.G. Camp II, R.D. Smith,
Utilizing humanblood plasma for proteomic biomarker discovery, J. Proteome
Res. 4 (2005) 1073–1085.
[19] A.K. Drukier, N. Ossetrova, E. Schors, G. Krasik, I. Grigoriev, C. Koenig, M.
Sulkowski, J. Holcman, L.R. Brown, J.E. Tomaszewski, M.D. Schnall, R.
Sainsbury, A.E. Lokshin, J. Godovac-Zimmermann, High-sensitivity blood-
based detection of breast cancer by multi photon detection diagnostic
proteomics, J. Proteome Res. 5 (2006) 1906–1915.
[20] G. MacBeath, S.L. Schreiber, Printing proteins as microarrays for high-
throughput function determination, Science 289 (2000) 1760–1763.
[21] D.H. David, J. Ptacek, M. Snyder, Protein microarray technology, Mech. Ageing
Dev. 128 (2007) 161–167.
[22] U. Korf, C. Lobke, O. Sahin, F. Haller, H. Sultmann, D. Arlt, A. Poustka, Reverse-
phase protein arrays for application-oriented cancer research, Proteomics Clin.
Appl. 3 (2009) 1140–1150.
[23] P. Peluso, D.S. Wilson, D. Do, H. Tran, M. Venkatasubbaiah, D. Quincy, B.
Heidecker, K. Poindexter, N. Tolani, M. Phelan, K. Witte, L.S. Jung, P. Wagner, S.
Nock, Optimizing antibody immobilization strategies for the construction of
protein microarrays, Anal. Biochem. 312 (2003) 113–124.
[24] P. Saviranta, R. Okon, A. Brinker, M. Warashina, J. Eppinger, B.H. Geierstanger,
Evaluating sandwich immunoassays in microarray format in terms of the
ambient analyte regime, Clin. Chem. 50 (2004) 1907–1920.
[25] W. Kusnezow, A. Jacob, A. Walijew, F. Diehl, J.D. Hoheisel, Antibody
microarrays: an evaluation of production parameters, Proteomics 3 (2003)
254–264.
[26] H. Zhu, J.F. Klemic, S. Chang, P. Bertone, A. Casamayor, K.G. Klemic, D. Smith, M.
Gerstein, M.A. Reed, M. Snyner, Analysis of yeast protein kinases using protein
chips, Nat. Genet. 26 (2000) 283–289.
[27] H. Lilja, A. Christensson, U. Dahlén, M.T. Matikainen, O. Nilsson, K. Pettersson,
T. Lövgren, Clin. Chem. 37 (1991) 1618–1625.[28] A. Christensson, C. Laurell, H. Lilja, Enzymatic activity of prostate-speciﬁc
antigen and its reactions with extracellular serine proteinase inhibitors, Eur. J.
Biochem. 194 (1990) 755–763.
[29] D. Liu, X. Huang, Z. Wang, A. Jin, X. Sun, L. Zhu, F. Wang, Y. Ma, G. Niu, A.
Walker, X. Chen, Gold nanoparticle-based activatable probe for sensing
ultralow levels of prostate-speciﬁc antigen, ACS Nano 7 (2013)
5568–5576.
[30] C. Thaxton, R. Elghanian, A. Thomas, S. Stoeva, J. Lee, N. Smith, A. Schaeffer, H.
Klocker, W. Horninger, G. Bartsch, C. Mirkin, Nanoparticle-based bio-barcode
assay redeﬁnes ‘‘undetectable’’ PSA and biochemical recurrence after radical
prostatectomy, PNAS 106 (2009) 18437–18442.
[31] D.M. Rissin, C.W. Kan, T.G. Campbell, S.C. Howes, D.R Fournier, L. Song, T. Piech,
P.P. Patel, L. Chang, A.J. Rivnak, E.P. Ferrell, J.D. Randall, G.K. Provuncher, D.R.
Walt, D.C. Duffy, Nat. Biotechnol. 28 (2010) 595–599.
[32] D. Wilson, D. Hanlon, G. Provuncher, L. Chang, L. Song, P. Patel, E.
Ferrell, H. Lepor, A. Partin, D. Chan, L. Sokoll, C. Cheli, R. Thiel, D.
Fournier, D. Duffy, Fifth-generation digital immunoassay for prostate-
speciﬁc antigen by single molecule array technology, Clin. Chem. 57
(2011) 1712–1721.
[33] K. Järås, A.A. Tajudin, A. Ressine, T. Soukka, G. Marko-Varga, A. Bjartell, J. Malm,
T. Laurell, H. Lilja, ENSAM: Europium Nanoparticles for Signal Enhancement of
Antibody Microarrays on nanoporous silicon, J. Proteome Res. 7 (2008) 1308–
1314.
[34] S.W. Lee, S. Kim, J. Malm, O.C. Jeong, H. Lilja, T. Laurell, Improved porous silicon
microarray based prostate speciﬁc antigen immunoassay by optimized surface
density of the capture antibody, Anal. Chim. Acta 796 (2013) 108–114.
[35] C. Stephan, K. Jung, T. Nakamura, G.M. Yousef, G. Kristiansen, E.P. Diamond,
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade
of prostate cancer, Int. J. Urol. 13 (2006) 238–243.
[36] V. Vaisanen, S. Eriksson, K.K. Ivaska, H. Lilja, M. Nurmi, K. Pettersson,
Development of sensitive immunoassays for free and total human glandular
kallikrein 2, Clin. Chem. 50 (2004) 1607–1617.
[37] H. Lilja, D. Ulmert, T. Bjork, C. Becker, M.A. Serio, J.A. Nilsson, P.A.
Abrahamsson, A.J. Vickers, G. Berglund, Long-term prediction of prostate
cancer up to 25 years before diagnosis of prostate cancer using prostate
kallikreins measured at age 44 to 50 years, J. Clin. Oncol. 25 (2007) 431–
436.
[38] T. Steuber, A.J. Vickers, A. Haese, C. Becker, K. Pettersson, F.K. Chun, M.W.
Kattan, J.A. Eastham, P.T. Scardino, H. Huland, H. Lilja, Risk assessment for
biochemical recurrence prior to radical prostatectomy: signiﬁcant
enhancement contributed by human glandular kallikrein 2 (hK2) and free
prostate speciﬁc antigen (PSA) in men with moderate PSA-elevation in serum,
Int. J. Cancer 118 (2006) 1234–1240.
